Citius Pharmaceuticals, Inc.: 10-Q filed 2012-02-14

Name: Citius Pharmaceuticals, Inc.: 10-Q filed 2012-02-14
Creator: Citius Pharmaceuticals, Inc.

What Citius Pharmaceuticals, Inc. reported in its quarterly report filed 2012-02-14 (fiscal Q1 2012): 24 published measures, 62 facts as tagged in accession 0001185185-12-000229.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-02-14
Fiscal period: fiscal Q1 2012
Accession: 0001185185-12-000229 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Citius Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-12-31	216	USD
At 2011-09-30	212	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2011-12-31	-26,409	USD
At 2011-09-30	-23,841	USD
At 2010-09-30	2,500	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2011-12-31	216	USD
At 2011-09-30	212	USD
At 2010-12-31	959	USD
At 2010-09-30	2,500	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	-2,568	USD	92
2010-09-09 to 2011-12-31	-44,409	USD	479
2010-10-01 to 2011-09-30	-26,341	USD	365
2010-10-01 to 2010-12-31	-9,008	USD	92
2009-10-01 to 2010-09-30	-15,500	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	-2,196	USD	92
2010-09-09 to 2011-12-31	-38,477	USD	479
2010-10-01 to 2010-12-31	-3,041	USD	92

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2011-10-01 to 2011-12-31	USD	92
2010-09-09 to 2011-12-31	USD	479
2010-10-01 to 2010-12-31	USD	92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	2,200	USD	92
2010-09-09 to 2011-12-31	38,693	USD	479
2010-10-01 to 2010-12-31	1,500	USD	92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Unit	Days
2011-10-01 to 2011-12-31	USD	92
2010-09-09 to 2011-12-31	USD	479
2010-10-01 to 2010-12-31	USD	92

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	18,000,000	shares	92
2010-10-01 to 2010-12-31	18,000,000	shares	92

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	18,000,000	shares	92
2010-10-01 to 2010-12-31	18,000,000	shares	92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	0	USD/shares	92
2010-10-01 to 2010-12-31	0	USD/shares	92

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	0	USD/shares	92
2010-10-01 to 2010-12-31	0	USD/shares	92

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2011-10-01 to 2011-12-31	USD	92
2010-09-09 to 2011-12-31	USD	479
2010-10-01 to 2010-12-31	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	-2,196	USD	92
2010-09-09 to 2011-12-31	-43,333	USD	479
2010-10-01 to 2010-12-31	-8,995	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-12-31	216	USD
At 2011-09-30	212	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	372	USD	92
2010-09-09 to 2011-12-31	1,076	USD	479
2010-10-01 to 2010-12-31	13	USD	92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-12-31	26,625	USD
At 2011-09-30	24,053	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2011-12-31	906	USD
At 2011-09-30	906	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	2,196	USD	92
2010-09-09 to 2011-12-31	43,333	USD	479
2010-10-01 to 2010-12-31	8,995	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2011-12-31	18,000,000	shares
At 2011-09-30	18,000,000	shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2011-12-31	3,950	USD
At 2011-09-30	3,950	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-10-01 to 2011-12-31	66	USD	92
2010-09-09 to 2011-12-31	12,253	USD	479
2010-10-01 to 2010-12-31	995	USD	92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2010-09-09 to 2011-12-31	18,000	USD	479

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2010-09-09 to 2011-12-31	906	USD	479
2010-10-01 to 2010-12-31	5,954	USD	92

Inspect the source

Entity: Citius Pharmaceuticals, Inc. / CIK 0001506251
Captured: 2026-09-20T09:12:24.553Z
SEC response SHA-256: dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))